Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;88(6):471-472.
doi: 10.1016/j.rhum.2021.02.023. Epub 2021 Mar 6.

Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française

[Article in French]
Alice Combier  1   2 , Sarah Wanono  1   2 , Lucile Poiroux  1   2 , Camélia Frantz  1   2 , Elise Descamps  1   2 , Olivier Fogel  1   2 , Margaux Boisson  1   2 , Xavier Ayral  1   2 , Cécile Bottois  1   2 , Yannick Allanore  1   2 , Jérôme Avouac  1   2
Affiliations

Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française

[Article in French]
Alice Combier et al. Rev Rhum Ed Fr. 2021 Dec.
No abstract available

PubMed Disclaimer

References

    1. Lopez-Medina C., Ladehesa-Pineda L., Gomez-Garcia I., et al. Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: a survey in 644 rheumatic patients. Joint Bone Spine. 2021;88:105085. - PMC - PubMed
    1. Lauper K., Mongin D., Iannone F., et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open. 2018;4:e000809. - PMC - PubMed
    1. Genovese M.C., Covarrubias A., Leon G., et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63:2854–2864. - PMC - PubMed
    1. Gupta R., Shipa M., Yeoh S.A., et al. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic. Rheumatology (Oxford) 2021;60:977–979. doi: 10.1093/rheumatology/keaa653. - DOI - PMC - PubMed

LinkOut - more resources